2.90Open2.30Pre Close24 Volume2.98K Open Interest17.50Strike Price7.40KTurnover77.92%IV1.93%PremiumJan 17, 2025Expiry Date2.17Intrinsic Value100Multiplier11DDays to Expiry0.38Extrinsic Value100Contract SizeAmericanOptions Type0.8287Delta0.0965Gamma8.03Leverage Ratio-0.0329Theta0.0041Rho6.65Eff Leverage0.0086Vega
Grail Stock Discussion
Larger Image: tradingview.com...
$Grail (GRAL.US)$
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England. Results from the first 25,000 PATHFINDER 2 participan...
No comment yet